STOCK TITAN

Evolent Health (EVH) director receives 41,096 restricted stock units in equity grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Jelinek Richard M reported acquisition or exercise transactions in this Form 4 filing.

Evolent Health, Inc. director Richard M. Jelinek reported an equity award of Class A common stock. He received 41,096 restricted stock units at no purchase price under the company’s Amended and Restated 2015 Omnibus Incentive Compensation Plan. These units vest on the earlier of June 4, 2027, or the company’s 2027 annual meeting, if he continues serving through that date.

After the award, he holds 77,533 shares of Class A common stock directly, with additional 15,000-share positions shown in each of two trusts as indirect holdings.

Positive

  • None.

Negative

  • None.
Insider Jelinek Richard M
Role null
Type Security Shares Price Value
Grant/Award Class A Common Stock 41,096 $0.00 --
holding Class A Common Stock -- -- --
holding Class A Common Stock -- -- --
Holdings After Transaction: Class A Common Stock — 77,533 shares (Direct, null); Class A Common Stock — 15,000 shares (Indirect, By the Richard M Jelinek Revocable Trust)
Footnotes (1)
  1. Represents restricted stock units granted to Mr. Jelinek pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. Securities vest on the earlier of June 4, 2027, and the date of the Company's 2027 annual meeting, subject to the reporting person's continued service on the vesting date.
RSU grant size 41,096 shares Restricted stock units of Class A Common Stock granted to Jelinek
Grant price $0.00 per share Price per share for the RSU award
Direct holdings after grant 77,533 shares Class A Common Stock directly held by Jelinek post-transaction
GST trust holdings 15,000 shares Class A Common Stock held by the Richard M. Jelinek GST
Revocable trust holdings 15,000 shares Class A Common Stock held by the Richard M. Jelinek Revocable Trust
Vesting date June 4, 2027 Latest vesting date for the 41,096 RSUs
restricted stock units financial
"Represents restricted stock units granted to Mr. Jelinek pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan financial
"Represents restricted stock units granted to Mr. Jelinek pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan."
vesting financial
"Securities vest on the earlier of June 4, 2027, and the date of the Company's 2027 annual meeting, subject to the reporting person's continued service on the vesting date."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Class A Common Stock financial
"security_title: Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Jelinek Richard M

(Last)(First)(Middle)
C/O EVOLENT HEALTH, INC.
1812 N. MOORE ST., STE. 1705

(Street)
ARLINGTON VIRGINIA 22209

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Evolent Health, Inc. [ EVH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock(1)06/04/2026A41,096(2)A$077,533D
Class A Common Stock15,000IBy the Richard M Jelinek Revocable Trust
Class A Common Stock15,000IBy the Richard M Jelinek GST
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents restricted stock units granted to Mr. Jelinek pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
2. Securities vest on the earlier of June 4, 2027, and the date of the Company's 2027 annual meeting, subject to the reporting person's continued service on the vesting date.
Remarks:
/s/ Jonathan Weinberg, Attorney-in-fact06/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Evolent Health (EVH) director Richard M. Jelinek report on this Form 4?

Richard M. Jelinek reported receiving 41,096 restricted stock units of Evolent Health Class A common stock. The award was made under the company’s Amended and Restated 2015 Omnibus Incentive Compensation Plan as part of his director compensation.

When do Richard M. Jelinek’s new Evolent Health (EVH) restricted stock units vest?

The 41,096 restricted stock units vest on the earlier of June 4, 2027, or the date of Evolent Health’s 2027 annual meeting, provided Jelinek continues to serve the company through the applicable vesting date.

How many Evolent Health (EVH) shares does Richard M. Jelinek hold after this grant?

Following the grant, Jelinek directly holds 77,533 shares of Evolent Health Class A common stock. In addition, the filing lists 15,000 shares held by the Richard M. Jelinek GST and 15,000 shares held by the Richard M. Jelinek Revocable Trust as indirect interests.

What is the transaction price for Richard M. Jelinek’s new Evolent Health (EVH) stock units?

The 41,096 restricted stock units were granted at a price per share of $0.00. This indicates they are compensation awards rather than open-market purchases, consistent with typical equity grants to directors of public companies.

Under which plan were Richard M. Jelinek’s Evolent Health (EVH) restricted stock units granted?

The restricted stock units were granted under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. This plan governs equity-based awards such as RSUs for directors, executives, and other eligible participants.